Baidu
map

Eur Urol:前列腺手术后男性尿道压力性尿失禁手术的非劣效性随机对照试验结果(MASTER)

2021-02-21 AlexYang MedSci原创

压力性尿失禁(SUI)是前列腺根治性切除术后的常见病,尽管进行了保守治疗,但很可能持续存在。吊带是一种新兴的治疗持续性SUI的手术,但缺乏与既有的人工尿道括约肌(AUS)的随机对照试验(RCT)比较。

压力性尿失禁(SUI)是前列腺根治性切除术后的常见病,尽管进行了保守治疗,但很可能持续存在。吊带是一种新兴的治疗持续性SUI的手术,但缺乏与既有的人工尿道括约肌(AUS)的随机对照试验(RCT)比较

最近,有研究人员比较了前列腺手术后尿流动力学SUI困扰的男性的手术效果。研究共包括了380名参与者。在随机化后第12个月,男性吊带的尿失禁率为134/154(87.0%),而AUS的尿失禁率为133/158(84.2%)(差异3.6%[95%CI-11.6至4.6],pNI=0.003),显示出非劣效性。失禁症状(ICIQ-UI SF)从基线时的16.1分和16.4分分别降低到8.7分(吊带)和7.5分(AUS)(平均差异1.4[95%CI 0.2到2.6],p=0.02)。严重的AEs(SAE)很少:吊带和AUS分别有6名和13名(一名男性有3个SAE)。生活质量评分有所改善,两组的满意度都很高。所有其他次要结果表明AUS更优。

最后,研究人员指出,尿失禁率较高且没有证据表明男性吊带和AUS之间存在差异。两组的症状和生活质量均有明显改善,男性对两种手术普遍满意。总的来说,二次分析和事后分析都有利于AUS

原始出处:

Paul Abrams , Lynda D Constable , David Cooper et al. Outcomes of a Noninferiority Randomised Controlled Trial of Surgery for Men with Urodynamic Stress Incontinence After Prostate Surgery (MASTER). Eur Urol. Feb 2021

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1712703, encodeId=864a1e1270361, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Jan 04 07:07:16 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819179, encodeId=518618191e9ce, content=<a href='/topic/show?id=5ac499329f0' target=_blank style='color:#2F92EE;'>#非劣效性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99329, encryptionId=5ac499329f0, topicName=非劣效性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Tue Dec 21 12:07:16 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775552, encodeId=cb0f1e755521a, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Sat Jan 15 09:07:16 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987293, encodeId=030a198e293c9, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Dec 20 13:07:16 CST 2021, time=2021-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769176, encodeId=a1251e69176bc, content=<a href='/topic/show?id=ebef4e52844' target=_blank style='color:#2F92EE;'>#尿道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47528, encryptionId=ebef4e52844, topicName=尿道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b63c37986505, createdName=lifestar, createdTime=Sun Jan 30 13:07:16 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907935, encodeId=7328190e935f8, content=<a href='/topic/show?id=b3c199328f2' target=_blank style='color:#2F92EE;'>#非劣效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99328, encryptionId=b3c199328f2, topicName=非劣效)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Wed Jan 19 13:07:16 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281683, encodeId=6e5f12816830c, content=<a href='/topic/show?id=0c3c4e407ec' target=_blank style='color:#2F92EE;'>#尿失禁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47407, encryptionId=0c3c4e407ec, topicName=尿失禁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Tue Feb 23 09:07:16 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296260, encodeId=10d81296260d6, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Tue Feb 23 09:07:16 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038999, encodeId=fd7f1038999c3, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Sun Feb 21 21:07:16 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926190, encodeId=b0c492619038, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Feb 21 18:33:42 CST 2021, time=2021-02-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1712703, encodeId=864a1e1270361, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Jan 04 07:07:16 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819179, encodeId=518618191e9ce, content=<a href='/topic/show?id=5ac499329f0' target=_blank style='color:#2F92EE;'>#非劣效性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99329, encryptionId=5ac499329f0, topicName=非劣效性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Tue Dec 21 12:07:16 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775552, encodeId=cb0f1e755521a, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Sat Jan 15 09:07:16 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987293, encodeId=030a198e293c9, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Dec 20 13:07:16 CST 2021, time=2021-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769176, encodeId=a1251e69176bc, content=<a href='/topic/show?id=ebef4e52844' target=_blank style='color:#2F92EE;'>#尿道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47528, encryptionId=ebef4e52844, topicName=尿道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b63c37986505, createdName=lifestar, createdTime=Sun Jan 30 13:07:16 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907935, encodeId=7328190e935f8, content=<a href='/topic/show?id=b3c199328f2' target=_blank style='color:#2F92EE;'>#非劣效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99328, encryptionId=b3c199328f2, topicName=非劣效)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Wed Jan 19 13:07:16 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281683, encodeId=6e5f12816830c, content=<a href='/topic/show?id=0c3c4e407ec' target=_blank style='color:#2F92EE;'>#尿失禁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47407, encryptionId=0c3c4e407ec, topicName=尿失禁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Tue Feb 23 09:07:16 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296260, encodeId=10d81296260d6, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Tue Feb 23 09:07:16 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038999, encodeId=fd7f1038999c3, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Sun Feb 21 21:07:16 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926190, encodeId=b0c492619038, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Feb 21 18:33:42 CST 2021, time=2021-02-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1712703, encodeId=864a1e1270361, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Jan 04 07:07:16 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819179, encodeId=518618191e9ce, content=<a href='/topic/show?id=5ac499329f0' target=_blank style='color:#2F92EE;'>#非劣效性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99329, encryptionId=5ac499329f0, topicName=非劣效性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Tue Dec 21 12:07:16 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775552, encodeId=cb0f1e755521a, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Sat Jan 15 09:07:16 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987293, encodeId=030a198e293c9, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Dec 20 13:07:16 CST 2021, time=2021-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769176, encodeId=a1251e69176bc, content=<a href='/topic/show?id=ebef4e52844' target=_blank style='color:#2F92EE;'>#尿道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47528, encryptionId=ebef4e52844, topicName=尿道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b63c37986505, createdName=lifestar, createdTime=Sun Jan 30 13:07:16 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907935, encodeId=7328190e935f8, content=<a href='/topic/show?id=b3c199328f2' target=_blank style='color:#2F92EE;'>#非劣效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99328, encryptionId=b3c199328f2, topicName=非劣效)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Wed Jan 19 13:07:16 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281683, encodeId=6e5f12816830c, content=<a href='/topic/show?id=0c3c4e407ec' target=_blank style='color:#2F92EE;'>#尿失禁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47407, encryptionId=0c3c4e407ec, topicName=尿失禁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Tue Feb 23 09:07:16 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296260, encodeId=10d81296260d6, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Tue Feb 23 09:07:16 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038999, encodeId=fd7f1038999c3, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Sun Feb 21 21:07:16 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926190, encodeId=b0c492619038, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Feb 21 18:33:42 CST 2021, time=2021-02-21, status=1, ipAttribution=)]
    2022-01-15 amyloid
  4. [GetPortalCommentsPageByObjectIdResponse(id=1712703, encodeId=864a1e1270361, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Jan 04 07:07:16 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819179, encodeId=518618191e9ce, content=<a href='/topic/show?id=5ac499329f0' target=_blank style='color:#2F92EE;'>#非劣效性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99329, encryptionId=5ac499329f0, topicName=非劣效性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Tue Dec 21 12:07:16 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775552, encodeId=cb0f1e755521a, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Sat Jan 15 09:07:16 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987293, encodeId=030a198e293c9, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Dec 20 13:07:16 CST 2021, time=2021-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769176, encodeId=a1251e69176bc, content=<a href='/topic/show?id=ebef4e52844' target=_blank style='color:#2F92EE;'>#尿道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47528, encryptionId=ebef4e52844, topicName=尿道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b63c37986505, createdName=lifestar, createdTime=Sun Jan 30 13:07:16 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907935, encodeId=7328190e935f8, content=<a href='/topic/show?id=b3c199328f2' target=_blank style='color:#2F92EE;'>#非劣效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99328, encryptionId=b3c199328f2, topicName=非劣效)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Wed Jan 19 13:07:16 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281683, encodeId=6e5f12816830c, content=<a href='/topic/show?id=0c3c4e407ec' target=_blank style='color:#2F92EE;'>#尿失禁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47407, encryptionId=0c3c4e407ec, topicName=尿失禁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Tue Feb 23 09:07:16 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296260, encodeId=10d81296260d6, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Tue Feb 23 09:07:16 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038999, encodeId=fd7f1038999c3, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Sun Feb 21 21:07:16 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926190, encodeId=b0c492619038, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Feb 21 18:33:42 CST 2021, time=2021-02-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1712703, encodeId=864a1e1270361, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Jan 04 07:07:16 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819179, encodeId=518618191e9ce, content=<a href='/topic/show?id=5ac499329f0' target=_blank style='color:#2F92EE;'>#非劣效性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99329, encryptionId=5ac499329f0, topicName=非劣效性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Tue Dec 21 12:07:16 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775552, encodeId=cb0f1e755521a, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Sat Jan 15 09:07:16 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987293, encodeId=030a198e293c9, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Dec 20 13:07:16 CST 2021, time=2021-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769176, encodeId=a1251e69176bc, content=<a href='/topic/show?id=ebef4e52844' target=_blank style='color:#2F92EE;'>#尿道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47528, encryptionId=ebef4e52844, topicName=尿道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b63c37986505, createdName=lifestar, createdTime=Sun Jan 30 13:07:16 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907935, encodeId=7328190e935f8, content=<a href='/topic/show?id=b3c199328f2' target=_blank style='color:#2F92EE;'>#非劣效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99328, encryptionId=b3c199328f2, topicName=非劣效)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Wed Jan 19 13:07:16 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281683, encodeId=6e5f12816830c, content=<a href='/topic/show?id=0c3c4e407ec' target=_blank style='color:#2F92EE;'>#尿失禁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47407, encryptionId=0c3c4e407ec, topicName=尿失禁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Tue Feb 23 09:07:16 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296260, encodeId=10d81296260d6, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Tue Feb 23 09:07:16 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038999, encodeId=fd7f1038999c3, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Sun Feb 21 21:07:16 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926190, encodeId=b0c492619038, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Feb 21 18:33:42 CST 2021, time=2021-02-21, status=1, ipAttribution=)]
    2022-01-30 lifestar
  6. [GetPortalCommentsPageByObjectIdResponse(id=1712703, encodeId=864a1e1270361, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Jan 04 07:07:16 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819179, encodeId=518618191e9ce, content=<a href='/topic/show?id=5ac499329f0' target=_blank style='color:#2F92EE;'>#非劣效性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99329, encryptionId=5ac499329f0, topicName=非劣效性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Tue Dec 21 12:07:16 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775552, encodeId=cb0f1e755521a, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Sat Jan 15 09:07:16 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987293, encodeId=030a198e293c9, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Dec 20 13:07:16 CST 2021, time=2021-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769176, encodeId=a1251e69176bc, content=<a href='/topic/show?id=ebef4e52844' target=_blank style='color:#2F92EE;'>#尿道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47528, encryptionId=ebef4e52844, topicName=尿道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b63c37986505, createdName=lifestar, createdTime=Sun Jan 30 13:07:16 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907935, encodeId=7328190e935f8, content=<a href='/topic/show?id=b3c199328f2' target=_blank style='color:#2F92EE;'>#非劣效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99328, encryptionId=b3c199328f2, topicName=非劣效)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Wed Jan 19 13:07:16 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281683, encodeId=6e5f12816830c, content=<a href='/topic/show?id=0c3c4e407ec' target=_blank style='color:#2F92EE;'>#尿失禁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47407, encryptionId=0c3c4e407ec, topicName=尿失禁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Tue Feb 23 09:07:16 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296260, encodeId=10d81296260d6, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Tue Feb 23 09:07:16 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038999, encodeId=fd7f1038999c3, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Sun Feb 21 21:07:16 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926190, encodeId=b0c492619038, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Feb 21 18:33:42 CST 2021, time=2021-02-21, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1712703, encodeId=864a1e1270361, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Jan 04 07:07:16 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819179, encodeId=518618191e9ce, content=<a href='/topic/show?id=5ac499329f0' target=_blank style='color:#2F92EE;'>#非劣效性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99329, encryptionId=5ac499329f0, topicName=非劣效性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Tue Dec 21 12:07:16 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775552, encodeId=cb0f1e755521a, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Sat Jan 15 09:07:16 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987293, encodeId=030a198e293c9, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Dec 20 13:07:16 CST 2021, time=2021-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769176, encodeId=a1251e69176bc, content=<a href='/topic/show?id=ebef4e52844' target=_blank style='color:#2F92EE;'>#尿道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47528, encryptionId=ebef4e52844, topicName=尿道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b63c37986505, createdName=lifestar, createdTime=Sun Jan 30 13:07:16 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907935, encodeId=7328190e935f8, content=<a href='/topic/show?id=b3c199328f2' target=_blank style='color:#2F92EE;'>#非劣效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99328, encryptionId=b3c199328f2, topicName=非劣效)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Wed Jan 19 13:07:16 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281683, encodeId=6e5f12816830c, content=<a href='/topic/show?id=0c3c4e407ec' target=_blank style='color:#2F92EE;'>#尿失禁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47407, encryptionId=0c3c4e407ec, topicName=尿失禁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Tue Feb 23 09:07:16 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296260, encodeId=10d81296260d6, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Tue Feb 23 09:07:16 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038999, encodeId=fd7f1038999c3, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Sun Feb 21 21:07:16 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926190, encodeId=b0c492619038, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Feb 21 18:33:42 CST 2021, time=2021-02-21, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1712703, encodeId=864a1e1270361, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Jan 04 07:07:16 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819179, encodeId=518618191e9ce, content=<a href='/topic/show?id=5ac499329f0' target=_blank style='color:#2F92EE;'>#非劣效性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99329, encryptionId=5ac499329f0, topicName=非劣效性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Tue Dec 21 12:07:16 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775552, encodeId=cb0f1e755521a, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Sat Jan 15 09:07:16 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987293, encodeId=030a198e293c9, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Dec 20 13:07:16 CST 2021, time=2021-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769176, encodeId=a1251e69176bc, content=<a href='/topic/show?id=ebef4e52844' target=_blank style='color:#2F92EE;'>#尿道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47528, encryptionId=ebef4e52844, topicName=尿道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b63c37986505, createdName=lifestar, createdTime=Sun Jan 30 13:07:16 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907935, encodeId=7328190e935f8, content=<a href='/topic/show?id=b3c199328f2' target=_blank style='color:#2F92EE;'>#非劣效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99328, encryptionId=b3c199328f2, topicName=非劣效)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Wed Jan 19 13:07:16 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281683, encodeId=6e5f12816830c, content=<a href='/topic/show?id=0c3c4e407ec' target=_blank style='color:#2F92EE;'>#尿失禁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47407, encryptionId=0c3c4e407ec, topicName=尿失禁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Tue Feb 23 09:07:16 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296260, encodeId=10d81296260d6, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Tue Feb 23 09:07:16 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038999, encodeId=fd7f1038999c3, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Sun Feb 21 21:07:16 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926190, encodeId=b0c492619038, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Feb 21 18:33:42 CST 2021, time=2021-02-21, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1712703, encodeId=864a1e1270361, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Jan 04 07:07:16 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819179, encodeId=518618191e9ce, content=<a href='/topic/show?id=5ac499329f0' target=_blank style='color:#2F92EE;'>#非劣效性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99329, encryptionId=5ac499329f0, topicName=非劣效性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Tue Dec 21 12:07:16 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775552, encodeId=cb0f1e755521a, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Sat Jan 15 09:07:16 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987293, encodeId=030a198e293c9, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Dec 20 13:07:16 CST 2021, time=2021-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769176, encodeId=a1251e69176bc, content=<a href='/topic/show?id=ebef4e52844' target=_blank style='color:#2F92EE;'>#尿道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47528, encryptionId=ebef4e52844, topicName=尿道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b63c37986505, createdName=lifestar, createdTime=Sun Jan 30 13:07:16 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907935, encodeId=7328190e935f8, content=<a href='/topic/show?id=b3c199328f2' target=_blank style='color:#2F92EE;'>#非劣效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99328, encryptionId=b3c199328f2, topicName=非劣效)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Wed Jan 19 13:07:16 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281683, encodeId=6e5f12816830c, content=<a href='/topic/show?id=0c3c4e407ec' target=_blank style='color:#2F92EE;'>#尿失禁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47407, encryptionId=0c3c4e407ec, topicName=尿失禁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Tue Feb 23 09:07:16 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296260, encodeId=10d81296260d6, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Tue Feb 23 09:07:16 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038999, encodeId=fd7f1038999c3, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Sun Feb 21 21:07:16 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926190, encodeId=b0c492619038, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Feb 21 18:33:42 CST 2021, time=2021-02-21, status=1, ipAttribution=)]
    2021-02-21 肿瘤克星

    高质量研究,读起来真爽,谢谢梅斯

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1712703, encodeId=864a1e1270361, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Tue Jan 04 07:07:16 CST 2022, time=2022-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1819179, encodeId=518618191e9ce, content=<a href='/topic/show?id=5ac499329f0' target=_blank style='color:#2F92EE;'>#非劣效性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99329, encryptionId=5ac499329f0, topicName=非劣效性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Tue Dec 21 12:07:16 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775552, encodeId=cb0f1e755521a, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Sat Jan 15 09:07:16 CST 2022, time=2022-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1987293, encodeId=030a198e293c9, content=<a href='/topic/show?id=bac5466546c' target=_blank style='color:#2F92EE;'>#对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46654, encryptionId=bac5466546c, topicName=对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad9f79, createdName=般若傻瓜, createdTime=Mon Dec 20 13:07:16 CST 2021, time=2021-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769176, encodeId=a1251e69176bc, content=<a href='/topic/show?id=ebef4e52844' target=_blank style='color:#2F92EE;'>#尿道#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47528, encryptionId=ebef4e52844, topicName=尿道)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b63c37986505, createdName=lifestar, createdTime=Sun Jan 30 13:07:16 CST 2022, time=2022-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907935, encodeId=7328190e935f8, content=<a href='/topic/show?id=b3c199328f2' target=_blank style='color:#2F92EE;'>#非劣效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99328, encryptionId=b3c199328f2, topicName=非劣效)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Wed Jan 19 13:07:16 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281683, encodeId=6e5f12816830c, content=<a href='/topic/show?id=0c3c4e407ec' target=_blank style='color:#2F92EE;'>#尿失禁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47407, encryptionId=0c3c4e407ec, topicName=尿失禁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Tue Feb 23 09:07:16 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296260, encodeId=10d81296260d6, content=<a href='/topic/show?id=7591984530b' target=_blank style='color:#2F92EE;'>#随机对照试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98453, encryptionId=7591984530b, topicName=随机对照试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373b263, createdName=lisa438, createdTime=Tue Feb 23 09:07:16 CST 2021, time=2021-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038999, encodeId=fd7f1038999c3, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Sun Feb 21 21:07:16 CST 2021, time=2021-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=926190, encodeId=b0c492619038, content=好文章!, beContent=null, objectType=article, channel=null, level=null, likeNumber=165, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Sun Feb 21 18:33:42 CST 2021, time=2021-02-21, status=1, ipAttribution=)]
    2021-02-21 jyzxjiangqin

    好文章!

    0

相关资讯

Sci Rep:使用前列腺特异性抗原密度预测临床显著性前列腺癌

最近,有研究人员评估了前列腺特异性抗原密度(PSAD)的预测价值,目的是为了对接受系统经直肠超声(TRUS)引导的前列腺活检男性进行检测。

Cancer Res:SIRT3的转录抑制增强了线粒体顺乌头酸酶的激活并促使侵袭性前列腺癌到骨质的转移

代谢失调是癌症进展的一个已知标志,然而促进代谢适应性以驱动转移性癌症的致癌信号仍不清楚。

盘点:前列腺疾病研究盘点(一)

前列腺是男性生殖器附属腺中最大的实质性器官。由前列腺组织和肌组织构成。前列腺炎是指由多种复杂原因引起的,以尿道刺激症状和慢性盆腔疼痛为主要临床表现的前列腺疾病。前列腺炎是泌尿外科的常见病,在泌尿外科5

盘点:前列腺疾病研究进展(二)

前列腺是男性生殖器附属腺中最大的实质性器官。由前列腺组织和肌组织构成。前列腺炎是指由多种复杂原因引起的,以尿道刺激症状和慢性盆腔疼痛为主要临床表现的前列腺疾病。前列腺炎是泌尿外科的常见病,在泌尿外科5

盘点:近期前列腺癌机制研究

【1】J Urol:去势敏感性和去势抵抗性前列腺癌的基因组变异比较分析

Baidu
map
Baidu
map
Baidu
map